GSK share price dips in London as Exdensur rollout and Feb 4 results loom

London, 08:41 GMT, January 30, 2026 — Regular session

GSK shares slipped 0.65% to 1,840 pence in early London trading on Friday. The stock kicked off at 1,836 pence, fluctuating between 1,823 and 1,843 pence. (London South East)

The move is modest, yet it underscores what’s driving the stock currently: execution. Investors have been swift to both fade and chase healthcare names this week, seeking fresh guidance and clearer insights on upcoming product launches.

CareMed, a U.S. specialty pharmacy, announced on Thursday that it has been chosen as a national specialty pharmacy provider for GSK’s Exdensur (depemokimab), targeting severe asthma. Benito Fernandez, the company’s chief commercial officer, said, “We are excited to partner with GSK to support the needs of patients with severe asthma.” (GlobeNewswire)

GSK climbed 1.9% to 18.52 pounds on Thursday, rebounding after slipping the day before. (Yahoo Finance UK)

Friday morning saw a steadier vibe across Europe, with the STOXX 600 nudging up 0.1%. Investors focused more on earnings reports and sector moves than on wider risk shifts. (Reuters)

The company has kept pace with the sector’s shifts. On Wednesday, the FTSE 100 edged down, dragged by healthcare and banking stocks. GSK dipped roughly 1.9%, mirroring AstraZeneca’s decline, Reuters noted. (Reuters)

Exdensur is the new launch that investors have been zeroing in on. The U.S. FDA gave the green light in December for the twice-yearly add-on treatment aimed at severe eosinophilic asthma in patients 12 and older, but it rejected approval for chronic rhinosinusitis with nasal polyps, Reuters reported. GSK contends that less-frequent dosing could give it an edge over asthma biologics like Sanofi and Regeneron’s Dupixent and Roche and Novartis’ Xolair, which usually require injections every two to four weeks. (Reuters)

The launch is still in its infancy, and partner announcements alone won’t cut it. What really matters now are uptake, payer coverage, and any moves to broaden the label. A sluggish rollout will be tough to spin positively.

GSK’s final results drop on Feb. 4, and investors will be watching closely for updated guidance and any early hints on Exdensur’s rollout. The company’s calendar also lists a first-quarter update slated for April 29. (London South East)

Shan Ahmed Khan Latest posts

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

View all

Analysts Lower Bank of America Price Targets But Remain Optimistic on BAC
January 30, 2026, 4:03 AM EST. On January 15, analysts from TD Cowen, Keefe, Bruyette & Woods, and Truist Securities lowered price targets for Bank of America Corporation (NYSE:BAC) following its stronger-than-expected Q4 2025 earnings. TD Cowen cut its target from $66 to $64, maintaining a Buy rating despite concerns over BAC's near-term operating leverage guidance sitting at the low end of the medium-term range. Similarly, Keefe, Bruyette & Woods and Truist trimmed their price targets to $63 and $60 respectively, while keeping Outperform and Buy ratings. The earnings beat, driven by lower provisions and net interest income gains, supports a largely intact revenue growth outlook. BAC remains a top profitable cheap stock, though some analysts suggest AI stocks may offer higher upside and lower risk at present.